Skip to main content

Table 4 Results for the reference case

From: Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema

 

Cost (€)

Incremental cost (€)

Efficacy (QALYs)

Incremental efficacy (QALYs)

ICER (€/QALY)

Aflibercept

92,340

4.134

Dexamethasone

169,689

77,349

6.80

2.667

29.002

  1. ICER: incremental cost-effectiveness ratio. QALY: quality-adjusted life year. Costs are presented in 2020 Euro